Addition of zoledronic acid to neoadjuvant chemotherapy is not beneficial in patients with HER2-negative stage II/III breast cancer: 5-year survival analysis of the NEOZOTAC trial (BOOG 2010-01)

Groot, S. de; Pijl, H.; Charehbili, A.; Ven, S. van de; Smit, V.T.H.B.M.; Meershoek-Klein Kranenbarg, E.; ... ; Dutch Breast Canc Res Grp (2019)

Article / Letter to editor

• Breast cancer
• Neoadjuvant chemotherapy
• Zoledronic acid
• Survival
• Insulin
• IGF-1R

• All authors: Groot, S. de; Pijl, H.; Charehbili, A.; Ven, S. van de; Smit, V.T.H.B.M.; Meershoek-Klein Kranenbarg, E.; Heijns, J.B.; Warmerdam, L.J.C. van; Kessels, L.W.; Dercksen, M.W.; Pepels, M.J.A.E.; Laarhoven, H.W.M. van; Vriens, B.E.P.J.; Putter, H.; Fiocco, M.; Liefers, G.J.; Hoeven, J.J.M. van der; Nortier, J.W.R.; Kroep, J.R.; Dutch Breast Canc Res Grp
• Date: 2019-08-28
• Journal: Breast Cancer Research
• Volume: 21
• Issue: 1
• DOI: doi:10.1186/s13058-019-1180-6